iTeos busts out early human data for anti-TIGIT antibody. Is it enough to match up with Roche, Merck?

The TIGIT protein has turned into an arms race for Big Pharma, with Merck and Roche looking to add their own candidates to checkpoint inhibitor combos. A smaller player in that race, iTeos Therapeutics, is one step behind those big names and is rolling out early data that looks pretty par for the course.